Trial Profile
Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled, 6-week Study to Evaluate the Safety, Tolerability and Pharmacodynamic Activity of Inhaled TPI 1020 in COPD Patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Feb 2024
Price :
$35
*
At a glance
- Drugs TPI 1020 (Primary) ; Budesonide
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Syntara Limited
- 04 Dec 2023 According to a Syntara Limited media release, Pharmaxis has changed its name to Syntara Limited
- 04 Mar 2009 Company (Pharmaxis) added to the associations field as reported by as reported by ClinicalTrials.gov.
- 04 Mar 2009 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.